ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis

Hee Kyung Ahn, Boram Han, Su Jin Lee, Taekyu Lim, Jong Mu Sun, Jin Seok Ahn, Myung Ju Ahn, Keunchil Park

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Anaplastic lymphoma kinase (ALK) inhibitor has shown dramatic efficacy in non-small cell lung cancer (NSCLC) patients harboring ALK rearrangements in phase I trial. Herein we report two cases of NSCLC patients with leptomeningeal carcinomatosis (LM), treated with ALK inhibitor under emergent use of investigational new drug combined with intrathecal methotrexate treatment. Progression free survival was 10 months and 6 months, respectively, and little additional toxicities were observed. These results suggest that ALK inhibitor might be safely administered even in patients or those with metastases in central nervous system.

Original languageEnglish
Pages (from-to)253-254
Number of pages2
JournalLung Cancer
Volume76
Issue number2
DOIs
StatePublished - May 2012

Keywords

  • ALK inhibitor
  • ALK positive NSCLC
  • Leptomeningeal carcinomatosis

Fingerprint

Dive into the research topics of 'ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis'. Together they form a unique fingerprint.

Cite this